P. Dodion

Results of an International Randomized Phase III Trial of the Mammalian Target of Rapamycin Inhibitor Ridaforolimus Versus Placebo to Control Metastatic Sarcomas in Patients After Benefit From Prior Chemotherapy

George D. Demetri, Sant P. Chawla, Isabelle Ray‐Coquard et al. · Journal of Clinical Oncology · 2013 · 239 citations

Common Mechanistic Pathways in Cancer and Heart Failure. A Scientific Roadmap on Behalf of the Translational Research Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)

Rudolf A. de Boer, Jean‐Sébastien Hulot, Carlo G. Tocchetti et al. · European Journal of Heart Failure · 2020 · 170 citations · Full text

Ridaforolimus as a single agent in advanced endometrial cancer: results of a single-arm, phase 2 trial

Nicoletta Colombo, D. Scott McMeekin, Peter E. Schwartz et al. · British Journal of Cancer · 2013 · 122 citations · Full text

The EORTC early clinical trials cooperative group experience with 5-aza-2′-deoxycytidine (NSC 127716) in patients with colo-rectal, head and neck, renal carcinomas and malignant melanomas

R Abele, M. Clavel, P. Dodion et al. · European Journal of Cancer and Clinical Oncology · 1987 · 118 citations

Malignant Melanomas, Radiation Medicine, Medicine +11

Randomized Phase II Trial of Ridaforolimus in Advanced Endometrial Carcinoma

Amit M. Oza, Sandro Pignata, Andrés Poveda et al. · Journal of Clinical Oncology · 2015 · 113 citations